Dr. Reddy’s semaglutide tablets is a prescription-based drug formulated using recombinant DNA (rDNA) origin of semaglutide active pharmaceutical ingredient (API)
| Photo Credit:
Jayasri R
Dr. Reddy’s Laboratories has launched its oral semaglutide biosimilar, indicated for type 2 diabetes mellitus in the Indian market.Dr. Reddy’s oral semaglutide is available in tablet form under the brand name Obeda. This launch follows Dr Reddy’s recent generic semaglutide injection launches in India and Canada, further establishing the company’s position as a full‑stack player in GLP‑1 therapies.“It can offer convenient, and flexible option which may support earlier treatment initiation, improving adherence and helping reduce the risk of long‑term complications,” the company said.Affordability FactorDr. Reddy’s Obeda (semaglutide tablets) is available in 3 mg, 7 mg and 14 mg strengths and recommended for once-daily oral use. It is priced at ₹99, ₹135, and ₹225 per tablet for the 3 mg, 7 mg, and 14 mg doses, respectively.“The launch of our oral semaglutide for patients with diabetes marks an important step in our journey to broaden access to advanced diabetes care. We recognise that every patient’s journey with diabetes is different, and treatment choices must reflect that diversity. With this launch, we are broadening our GLP‑1 portfolio to offer patients more choice and flexibility,” MV Ramana, CEO, Global Generics, Dr. Reddy’s said in a release on Wednesday.“As the products developed and formulated in-house, we are committed to reliable supply and consistent quality for patients in India. As we continue to build a comprehensive GLP‑1 portfolio, we are focused on delivering innovation, high-quality, and affordability, translating into meaningful treatment options and better long-term outcomes for people living with chronic metabolic diseases in India and beyond,'’ he added.Diabetes NumbersDr. Reddy’s Obeda (semaglutide tablets), a prescription-based drug, is formulated using recombinant DNA (rDNA) origin of semaglutide active pharmaceutical ingredient (API). The Hyderabad-based company obtained approval for its oral semaglutide biosimilar from the CDSCO following a review of a Phase III clinical study enrolling 288 participants with type 2 diabetes mellitus conducted in India.As per the ICMR‑INDIAB study, India represents one of the world’s largest diabetes burdens with over 101 million adults living with the condition and a prevalence of 11.4 per cent. Alarmingly, nearly 136 million individuals are prediabetic, and close to 40 per cent of adults have abdominal obesity, placing them at high risk of progression.Published on May 20, 2026
